Thursday, 22 October 2009

Mike Lucas on Low Dose Naltrexone

Michael Moore's colleague Mike Lucas weighs on the Low Dose Naltrexone issue -

Why won’t the drug companies shell out cash for a promising drug that requires FDA approval?

1 comment:

  1. I have to assume that the failure of LDN to become mainstream in 30 years is due to institutional paranoia and toadying to the demands of the pharmaceutical industry by the doctors themselves who are free to prescribe LDN as a safe drug as long as they avoid wild claims of it’s effects. LDN is the biggest discovery in therapy since penicillin when you consider how many deadly diseases it can treat, and treat them safely without killer side effects. Een if it is cheap and will affect pharmaceutical industry share values, it must be made available to all, after all, we value life over wealth, don't we?